Pretomanid
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Pretomanid: From Drug-Resistant Tuberculosis to Candidiasis
One-Sentence Summary
Pretomanid is a nitroimidazooxazine antimycobacterial, used globally as part of the BPaL regimen (Bedaquiline + Pretomanid + Linezolid) for extensively drug-resistant (XDR) and treatment-intolerant multidrug-resistant (MDR) pulmonary tuberculosis. The TxGNN model predicts it may be effective for Candidiasis, but this prediction is currently supported by 0 clinical trials and 0 publications, and the drug’s own mechanism of action provides no plausible link to antifungal activity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Taiwan regulatory data (drug is not marketed in Taiwan). Based on the drug’s evidence records, it is globally approved as part of the BPaL regimen for extensively drug-resistant / treatment-intolerant MDR pulmonary tuberculosis. |
| Predicted New Indication | Candidiasis |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| US Market Status | 未上市 (Not marketed in Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Pretomanid is a nitroimidazooxazine prodrug that requires activation by the mycobacteria-specific enzyme deazaflavin-dependent nitroreductase (Ddn). Once activated, it generates reactive nitrogen species that inhibit mycolic acid synthesis under aerobic conditions, or act as a respiratory poison under anaerobic conditions. Both the activating enzyme system and the downstream target are specific to the Mycobacterium genus.
Candida species are fungi with a fundamentally different cell wall structure and no known Ddn-homologous activation pathway. There is no mechanistic basis connecting pretomanid’s mode of action to antifungal activity. The evidence pack’s own mechanistic rationale explicitly flags this: the high TxGNN score most likely reflects a generalized “antimicrobial agent” node linkage in the knowledge graph, rather than a target-specific biological relationship.
For context, the same evidence pack also evaluated leprosy (Mycobacterium leprae) as a candidate — a much more biologically plausible hypothesis given the shared genus. However, direct in-vitro evidence (PMID 17005816) shows M. leprae is naturally resistant to pretomanid (PA-824), refuting that hypothesis as well. This suggests the model’s high-ranking candidates for this drug should be treated with particular caution until mechanism-consistent evidence emerges.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No Taiwan/US market authorization data available — pretomanid is not currently marketed in Taiwan (0 licenses on record).
Safety Considerations
Please refer to the package insert for safety information.
(Note: Two data gaps were flagged in the evidence pack — TFDA label warnings/contraindications [Blocking severity] and detailed MOA documentation [High severity] — both currently unresolved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The candidiasis prediction has no clinical or literature support (Evidence Level L5) and no plausible mechanistic link — pretomanid’s target (mycobacterial Ddn-mediated mycolic acid synthesis/respiratory inhibition) does not exist in fungal pathogens like Candida. This looks like a knowledge-graph artifact rather than a genuine repurposing signal.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (Blocking data gap, DG001) — required before any safety pre-assessment (S1) can begin
- Confirmed mechanism of action documentation from DrugBank (High priority, DG002)
- Any in-vitro or preclinical antifungal activity data for pretomanid specifically against Candida species, to substantiate or refute the TxGNN signal
- Given that the next-ranked candidate (leprosy) has direct refuting in-vitro evidence, and the remaining candidates (coronary artery disease, myocardial ischemia, ALCAPA) have no mechanistic rationale at all, no candidate in this evidence pack currently warrants advancement beyond Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.